A new collaborative study led by researchers at Sanford-Burnham, published today in Cell Reports, provides new insight into the molecular changes that lead to resistance to a commonly prescribed group of drugs called BRAF inhibitors. The findings suggest that targeting newly discovered pathways could be an effective approach to improving the clinical outcome of patients with BRAF inhibitor-resistant melanoma tumors. Continue reading “Sanford-Burnham researchers identify a new target for treating drug-resistant melanoma”
Institute News